Aradigm Corporation Культура компании

Dr. Igor Gonda, Ph.D. has been the Chief Executive Officer and President at Aradigm Corporation since August 2006 and its Executive Director since September 2001. Dr. Gonda served as the Chief Executive Officer and Managing Director of ACRUX Limited. from December 2001 to August 10, 2006. He has an extensive experience in building entrepreneurial research and development groups and corporate partnerships in the pharmaceutical industry. He served as the Chief Scientific Officer of Aradigm Corp. from July 2001 to December 2001 and also served as its Vice President of Research and Development from October 1995 to July 2001. From February 1992 to September 1995, Dr. Gonda served as a Senior Scientist and Group Leader at Genentech, Inc. with responsibility for all non-oral drug delivery. He served as the Chairman of Scientific Advisory Board at Aradigm Corporation until August 2006. Dr. Gonda served as the Chairman of Scientific Board at Exhale Therapeutics, Inc. He serves as a Director of The Alpha-1 Project, Inc. He served as a Director of ACRUX Ltd. from 2002 to October 31, 2006. He served as a Member of Scientific Advisory Board at Aradigm Corp. Dr. Gonda held academic positions at the University of Aston in Birmingham, UK and the University of Sydney, Australia. He also was on the founding Board of Directors of the International Pharmaceutical Aerosol Consortium of Regulatory Science. Dr. Gonda has a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, UK. Director

Ms. Nancy E. Pecota has been the Chief Financial Officer and Vice President of Finance at Aradigm Corporation since September 22, 2008 and serves as its Corporate Secretary. Ms. Pecota has more than 20 years of experience in corporate accounting and operations management. She served as the Chief Financial Officer of NuGEN Technologies, Inc., from October 2005 to July 2008. From August 2003 to September 2005, Ms. Pecota served as an Executive Financial Consultant to early- and mid-stage life sciences companies, developing fundable business models and assessing and improving internal financial preparation and reporting processes. From March 2001 to April 2003, Ms. Pecota served as a Vice President of Finance and Administration at Signature BioScience, Inc., and Director of Finance and Accounting for ACLARA BioSciences, Inc. She began her career as Financial Analyst at Westinghouse Electric Corporation, later serving in several management positions before becoming corporate controller at Dpix, Inc. Ms. Pecota was named in the San Francisco Business Times 100 Most Influential Bay Area Business Women in 2002 and 2003. She holds Bachelor of Science in Economics from San Jose State University. Ms. Pecota was among the executives named in the San Francisco Business Times 100 Most Influential Bay Area Business Women in 2002 and 2003.

Dr. Juergen Froehlich, MD, MBA, FCPh, has been the Chief Medical Officer at Aradigm Corporation since November 19, 2013. Dr. Froehlich joined Aradigm from Vertex Pharmaceuticals where he was the Head of Regulatory Affairs, oversaw global submissions and approvals under accelerated review timelines of Kalydeco (ivacaftor) and the granting of two Breakthrough Designations for the orphan indication of cystic fibrosis. Dr. Froehlich has more than 20 years of pharmaceutical industry experience in preclinical, clinical and regulatory activities at Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers Squibb, Ipsen and Vertex Pharmaceuticals. While at Genentech, Dr. Froehlich directed the clinical development, submission and approval of Activase for acute ischemic stroke and the early development of Xolair for the treatment of allergic rhinitis and allergic asthma. At Bristol-Myers Squibb, Dr. Froehlich oversaw the global life cycle management for Plavix and Avapro. At Ipsen, he directed the FDA submission and approval for Somatuline for acromegaly, oversaw U.S. development of Dysport for cervical dystonia as well as global clinical studies and regulatory strategies for recombinant porcine factor VIII in hemophilia. Prior to this, he was Clinical and Developmental Pharmacological Sciences at Ipsen, Milford, Mass., and before that vice president of Global Medical Affairs and clinical leader of the BristolMyers Squibb/Sanofi International Alliance, where he oversaw all global development, life cycle and post marketing activities for clopidogrel, irbesartan and pravastatin. Previously, Dr. Froehlich was head of section for Antithrombotic and Fibrinolytic Drugs at Boehringer Ingelheim in Biberach,Germany, directing clinical trials for acute myocardial infarction, pulmonary embolism, acute stroke and clearance of arteriovenous shunts. Dr. Froehlich serves as Member of Clinical Advisory Board at Thrombolytic Science International, LLC. Dr. Froehlich was closely involved in the commercialization of various drugs and biologics and alliance activities with other companies. Dr. Froehlich was clinical strategy leader for all Genentech stroke projects and a member of the corporate cardiovascular advisory committee. He is a Diplomate of the American Board of Clinical Pharmacology, a Fellow of the American College of Clinical Pharmacology and a Fellow of the Faculty of Pharmaceutical Medicine. Dr. Froehlich graduated from the Medical School at Wuerzburg University in Germany. Dr. Froehlich also holds a dual Executive MBA degree from the Graduate School of Business Administration in Zurich, Switzerland and from the State University of New York at Albany.

Meredith Callender serves as the Executive Director of Human Resources of Aradigm Corporation. Meredith started at Aradigm Corporation in January of 2016. Meredith currently resides in San Francisco Bay Area.

Edwin Gordon serves as the Member Board Of Directors of Aradigm Corporation. Edwin started at Aradigm Corporation in January of 2018. Edwin currently resides in Greater New York City Area.

Juergen Froehlich serves as the Chief Medical Officer of Aradigm Corporation. Juergen started at Aradigm Corporation in November of 2013. Juergen currently resides in Greater Boston Area.